Jim Simons
SPRB

Jim Simons’s Spruce Biosciences SPRB Stock Holding History

Jim Simons’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,105
Closed -$111K – 3993
2025
Q1 		$111K Sell
5,105
-307
-6% -$8.55K ﹤0.01% 3180
2024
Q4 		$170K Sell
5,412
-2,717
-33% -$99.6K ﹤0.01% 3205
2024
Q3 		$290K Buy
8,129
+3,248
+67% +$119K ﹤0.01% 2994
2024
Q2 		$190K Buy
4,881
+1,268
+35% +$68K ﹤0.01% 3056
2024
Q1 		$213K Buy
3,613
+1,145
+46% +$291K ﹤0.01% 3209
2023
Q4 		$542K Sell
2,468
-302
-11% -$34.9K ﹤0.01% 2739
2023
Q3 		$470K Sell
2,770
-418
-13% -$70.4K ﹤0.01% 2727
2023
Q2 		$514K Buy
3,188
+1,053
+49% +$176K ﹤0.01% 2857
2023
Q1 		$354K Buy
2,135
+289
+16% +$53.7K ﹤0.01% 3050
2022
Q4 		$152K Sell
1,846
-62
-3% -$5.19K ﹤0.01% 3506
2022
Q3 		$196K Sell
1,908
-111
-5% -$15.5K ﹤0.01% 3393
2022
Q2 		$263K Buy
2,019
+530
+36% +$67.9K ﹤0.01% 3526
2022
Q1 		$225K Buy
1,489
+958
+180% +$178K ﹤0.01% 3601
2021
Q4 		$178K Buy
531
+78
+17% +$23.2K ﹤0.01% 3555
2021
Q3 		$204K Buy
+453
New +$284K ﹤0.01% 3199

Other funds holding SPRB

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $265M AUM 30.15% 1-Year Est. Return

Jim Simons's SPRB Position: Q2 2025 in Review

Jim Simons sold out of Spruce Biosciences (SPRB) in Q2 2025, closing a stake of 5,105 shares — an estimated $111K sold.

Jim Simons first reported a position in SPRB in Q3 2021 and held it in 15 quarters. The position peaked at $542K in Q4 2023. 3 funds tracked by Wall St. Rank hold SPRB as of Q2 2025.

  • Jim Simons reported no remaining Spruce Biosciences position as of Q2 2025 after selling out during the quarter.
  • Jim Simons sold 5,105 Spruce Biosciences shares in Q2 2025, an estimated $111K.
  • Jim Simons first reported a position in Spruce Biosciences in Q3 2021 and held it in 15 quarters.
  • Jim Simons's Spruce Biosciences position peaked at $542K in Q4 2023.
  • 3 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2025.

Based on Renaissance Technologies's 13F filing for Q2 2025, filed 13 Aug 2025.